William Blair analyst Sami Corwin has maintained their bullish stance on ACLX stock, giving a Buy rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sami Corwin has given his Buy rating due to a combination of factors related to the promising efficacy and safety profile of Arcellx Inc’s anito-cel treatment for relapsed/refractory multiple myeloma. The updated data from the iMMagine-1 study showed a high overall response rate of 97%, with a significant portion of patients achieving complete responses. Moreover, the progression-free survival and overall survival rates at 6 and 12 months were notably high, indicating the potential for long-term benefits.
Sami Corwin also highlighted the safety advantages of anito-cel, particularly the absence of severe neurotoxicity events, which sets it apart from similar treatments like Legend’s Carvykti. The lack of additional treatment-related deaths or severe cytokine release syndrome further supports the treatment’s favorable safety profile. These compelling clinical outcomes, despite broader market pressures, underpin the Buy rating for Arcellx Inc’s stock.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $115.00 price target.